New Mapping and Treatment Method for Atrial Fibrillation
(COAST-AF Trial)
Trial Summary
What is the purpose of this trial?
This is a pilot study to assess the usefulness of ECG mapping, and enhanced MRI and PET scan imaging in identifying atrial fibrosis and arrhythmia circuits involved in persistent atrial fibrillation and in guiding an innovative AF catheter ablation strategy. It is hypothesized that identifying these critical arrhythmia circuits and atrial fibrosis with enhanced imaging and performing an individualized innovative AF catheter ablation will result in higher procedural success rates.
Research Team
Pablo B Nery, MD
Principal Investigator
Ottawa Heart Institute Research Corporation
Robert deKemp, PhD
Principal Investigator
Ottawa Heart Institute Research Corporation
Elena Pena, MD
Principal Investigator
The Ottawa Hospital
David H Birnie, MD
Principal Investigator
Ottawa Heart Institute Research Corporation
Eligibility Criteria
This trial is for adults aged 18-80 with symptomatic persistent atrial fibrillation, who have had an episode lasting more than 7 days in the past year and are due for AF catheter ablation. It's not suitable for those with reversible causes of AF, previous ablations, heart thrombus, severe valve disease, kidney issues or conditions preventing MRI scans.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- AF Catheter Ablation (Procedure)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ottawa Heart Institute Research Corporation
Lead Sponsor
Dr. Thierry Mesana
Ottawa Heart Institute Research Corporation
Chief Medical Officer since 2014
MD from McGill University
Dr. Rob Beanlands
Ottawa Heart Institute Research Corporation
Chief Executive Officer since 2024
MD from the University of Ottawa